- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
External Trigeminal Nerve Stimulation device effective for At-Home Acute Migraine Treatment: Phase 3 Clinical Trial
DARIEN, CEFALY Technology, a Belgium-based manufacturer of wearable medical devices for migraine, today announced the results of a clinical study demonstrating that two-hour treatment with the e-TNS CEFALY device is a safe and effective, non-pharmaceutical alternative for the acute treatment of migraine attacks in the out-of-hospital setting.
The Trial of e-TNS for the Acute treatment of Migraine (TEAM) study was the first, prospective, double-blind,randomized, sham-controlled clinical trial of 2-hour e-TNS treatment for acute migraine attack in an at-home scenario. The TEAM study is also the largest sham-controlled, clinical trial examining the use of any e-TNS therapy for the treatment of migraine headache.
A common and debilitating neurological disorder, migraine has been ranked by the World
Health Organization as the world's second leading cause of disability. There are several limitations to conventional anti-migraine medications. In addition, many patients prefer to avoid medications to treat their migraine headaches. As a result, up to 40% of migraine patients have unmet needs for this migraine treatment.
External trigeminal nerve stimulation (e-TNS) is a medical device treatment that offers a non-pharmacological, non-invasive approach for patients with migraine who prefer to avoid medications, have intolerances to medications or, require complementary therapy in their migraine management. Worn on the forehead, the CEFALY e-TNS device delivers a mild electric stimulation to reduce pain signals of the trigeminal nerve, a primary pathway for migraine pain.
The TEAM study spanned nine months and was conducted at 10 centers across the United States. The study enrolled 538 patients aged 18-65 with episodic migraine, with or without aura, who had moderate- to severe-intensity migraine attacks 2 to 8 times per month. Subjects who met all of the study criteria were randomly assigned to either the verum or sham group and were provided a headache diary and educated with how to use the CEFALY device.
During a 2 month period, patients were instructed to self-administer the e-TNS treatment, according to the training and instruction they received, within 4 hours of migraine onset or within 4 hours of awakening with migraine headache. Neurostimulation was applied with the CEFALY e-TNS device for a 2-hour, continuous session.
In the verum group, compared to the sham group:
Pain freedom at 2 hours was 7.2% higher (25.5% compared to 18.3%; p = .043)
Resolution of the most bothersome migraine-associated symptom was 14.1% higher (56.4% compared to 42.3%; p = 0.001)
Pain relief at 2 hours was 14.3% higher (69.5% compared to 55.2%; p = 0.001)
Absence of all migraine-associated symptoms at 2 hours was 8.4% higher (42.5% compared to 34.1%; p = 0.044)
Sustained pain freedom and pain relief at 24 hours was 7.0% and 11.5% higher in verum (22.8% and 45.9%) than sham (15.8 and 34.4%; p = 0.039)
No serious adverse events were reported.
Study authors concluded that the use of self-administered 2-hour e-TNS therapy is a safe and effective therapeutic option, with or without the use of acute anti-migraine medications.
"The CEFALY device provides patients with a non-medication option for the prevention and acute treatment of migraine. It is especially helpful to add to a medication regimen or use for people who have had a negative experience with migraine medications," said Dr. Deena Kuruvilla, one of the study authors and Medical Director and Board Certified Neurologist, Westport Headache Institute.
"So many people who live with migraine pain are desperate for a solution that they can use safely at home," said Jen Trainor McDermott, CEO of CEFALY Technology. "As the TEAM study shows us, CEFALY provides the powerful, sustained pain relief they need."
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751